Allarity expands Phase 2 stenoparib trial to three ovarian cancer patient cohorts
ALLR•
ALLR•Allarity Therapeutics expanded its Phase 2 stenoparib trial in advanced ovarian cancer to three cohorts, including patients with primary platinum-refractory disease or clinically evaluable disease that cannot be measured under standard criteria. Earlier findings included a confirmed complete response; further data will be released at future conferences.
Allarity Therapeutics expanded its Phase 2 stenoparib trial in advanced ovarian cancer to three patient cohorts. Newly eligible patients include those with primary platinum-refractory disease or clinically evaluable disease that cannot be measured under standard criteria.
The cohorts will be evaluated independently, and a strong result in any group could support further development. Findings presented at the ESMO Gynaecological Cancers Congress in June 2026 showed durable clinical benefit, including a confirmed complete response. Additional clinical and scientific data will be released at future conferences.